HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. [electronic resource]
Producer: 20120518Description: 10 p. digitalISSN:- 1479-5876
- Adult
- Aged
- Antibiotics, Antineoplastic -- pharmacology
- Antigens, Neoplasm -- genetics
- Breast Neoplasms -- drug therapy
- Chemotherapy, Adjuvant
- DNA Topoisomerases, Type II -- genetics
- DNA-Binding Proteins -- genetics
- Dose-Response Relationship, Drug
- Epirubicin -- pharmacology
- Female
- Gene Expression Profiling
- Gene Expression Regulation, Neoplastic -- drug effects
- Genes, Neoplasm -- genetics
- Humans
- Ki-67 Antigen -- metabolism
- Middle Aged
- Multivariate Analysis
- Paraffin Embedding
- Poly-ADP-Ribose Binding Proteins
- Proportional Hazards Models
- RNA, Messenger -- genetics
- Receptor, ErbB-2 -- genetics
- Receptors, Estrogen -- metabolism
- Receptors, Progesterone -- metabolism
- Risk Factors
- Tissue Fixation
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.